Mesoblast Ltd
USUSDMesoblast Ltd (US:MEOBF) — Biotechnology: Biological Products (No Diagnostic Substances). Numărul de burse pe care se tranzacționează acțiunile companiei: 2. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre Companie
- Site Web
- mesoblast.com
- Relații cu Investitorii
- investorsmedia.mesoblast.com/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sediu Central
- MELBOURNE, VICTORIA, Australia
- Director General
- Silviu Itescu
- Angajați
- 108
- Acțiuni în Circulație
- 1.3 mld. la 2026-06-30
- Free Float
- 861.1 mil.
- Capitalizare de Piață
- 1.48 mld. USD
- Insideri
- 36.28%
- Investitori Instituționali
- 17.44%
- Industrie (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- AU000000MSB8
- FCF
- −60.6 mil. USD
- Datorie
- 127 mil. USDnumerar net
- Câștiguri și FCF — pentru cele 12 luni până la 31.12.2025 (cel mai recent raport al companiei).
Descriere
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Cei Mai Mari Acționari
| Deținător | Participație | Acțiuni | Data Raportului |
|---|---|---|---|
| Itescu (Silviu) (Chief E… | ≈6.23% | 80.84 mil. | 2026-07-17 |
| VANGUARD STAR FUNDS-Vang… | 1.05% | 13.66 mil. | 2026-04-30 |
| VANGUARD TAX-MANAGED FUN… | 0.62% | 8.01 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.53% | 6.88 mil. | 2026-07-31 |
| Rose (Eric) (Director (N… | ≈0.52% | 6.75 mil. | 2026-01-09 |
| DFA INVESTMENT TRUST CO-… | 0.36% | 4.68 mil. | 2026-04-30 |
| VANGUARD Intl Eqy. INDEX… | 0.27% | 3.51 mil. | 2026-04-30 |
| iShares Trust-iShares MS… | 0.24% | 3.07 mil. | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.15% | 1.99 mil. | 2026-05-31 |
| Dimensional ETF Trust-Di… | 0.11% | 1.38 mil. | 2026-04-30 |
| iShares Trust-iShares Co… | 0.09% | 1.23 mil. | 2026-07-31 |
| SPDR INDEX SHARES Fd.S-S… | 0.09% | 1.19 mil. | 2026-08-31 |
| Bell (Jane Catherine) (D… | ≈0.05% | 622 492 | 2025-02-28 |
| Burns (William) (Indepen… | ≈0.02% | 226 250 | 2025-10-21 |
| Legato Capital Managemen… | 0.01% | 47 380 | 2022-06-30 |
| Cobley (Lyn Elizabeth) (… | ≈0% | 63 000 | 2026-01-09 |
Conectează-te cu Google